AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22516476 — intervention group
Group type: COMPARATOR
Intervention: Pressure Support Ventilation (PSV)
Number of subjects: 36
Study 21316535 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) administered with a 2-week interval between doses
Number of subjects: 240
Study 21316535 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) administered with a 3-week interval between doses
Number of subjects: 240
Study 21316535 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) administered with a 6-week interval between doses
Number of subjects: 240
Study 21316535 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) with a 2-week interval
Number of subjects: 240
Study 21316535 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses) with a 3-week interval
Number of subjects: 240
Study 21316535 — intervention group
Group type: EXPERIMENTAL
Intervention: MF59-adjuvanted H5N1 influenza vaccine (7.5-μg doses)
Number of subjects: 240
Study 17977472 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin and mineral supplement
Number of subjects: 45
Study 17977472 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 15505873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonographic screening for AAA
Number of subjects: 67800
Study 15505873 — intervention group
Group type: COMPARATOR
Intervention: Control group (no invitation for screening)
Number of subjects: 67800
Study 11765544 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch procedure
Number of subjects: 157
Study 9509206 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 ml of compound sodium lactate solution during surgery
Number of subjects: 100
Study 9509206 — intervention group
Group type: COMPARATOR
Intervention: No intraoperative fluid
Number of subjects: 100
Study 7528160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervolemic hemodilution (HHD): Infusion of 15 ml/kg bodyweight hydroxyethyl starch (200/0.5)
Number of subjects: 49
Study 7528160 — intervention group
Group type: COMPARATOR
Intervention: Acute normovolemic hemodilution (ANH): Withdrawal of 15 ml/kg bodyweight autologous blood and isovolemic replacement by hydroxyethyl starch (200/0.5)
Number of subjects: 49
Study 7528160 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypervolemic hemodilution (HHD)
Number of subjects: 49
Study 7528160 — intervention group
Group type: COMPARATOR
Intervention: Acute normovolemic hemodilution (ANH)
Number of subjects: 49
Study 2494454 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (1.5 million units over 30 minutes)
Number of subjects: 270
Study 2494454 — intervention group
Group type: COMPARATOR
Intervention: Intravenous recombinant tissue plasminogen activator (rt-PA) (100 mg over three hours)
Number of subjects: 270
Study 8507540 — intervention group
Group type: EXPERIMENTAL
Intervention: PAC plus SPG combination therapy
Number of subjects: 68
Study 8507540 — intervention group
Group type: COMPARATOR
Intervention: PAC therapy
Number of subjects: 68
Study 391258 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0
Study 391258 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0
Study 30621742 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-shot sciatic nerve block with 2 mg/ml ropivacaine, 20 ml
Number of subjects: 40
Study 30621742 — intervention group
Group type: COMPARATOR
Intervention: No sciatic nerve block
Number of subjects: 40
Study 28383451 — intervention group
Group type: EXPERIMENTAL
Intervention: Karydakis procedure with tie‐over compressing sutures without a drain
Number of subjects: 154
Study 28383451 — intervention group
Group type: COMPARATOR
Intervention: Standard Karydakis procedure
Number of subjects: 154
Study 26370384 — intervention group
Group type: EXPERIMENTAL
Intervention: Preformed metal crowns placed using a polyvinyl siloxane occlusal template
Number of subjects: 60
Study 26370384 — intervention group
Group type: COMPARATOR
Intervention: Preformed metal crowns placed without the use of an occlusal template (Control)
Number of subjects: 60
Study 23399660 — intervention group
Group type: EXPERIMENTAL
Intervention: MyPyramid and supplementary information about n-3 fatty acids
Number of subjects: 88
Study 23399660 — intervention group
Group type: COMPARATOR
Intervention: Control group (MyPyramid only)
Number of subjects: 88
Study 21422239 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium 2,2 dimethylbutyrate (SDMB) at doses of 2, 5, 10, and 20 mg/kg single dose or 5, 10, or 15 mg/kg daily for 14 days
Number of subjects: 0
Study 21422239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19972627 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-1 (last positive stage of the Talk Test)
Number of subjects: 14
Study 19972627 — intervention group
Group type: EXPERIMENTAL
Intervention: LP (last positive stage of the Talk Test)
Number of subjects: 14
Study 19972627 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ (first equivocal stage of the Talk Test)
Number of subjects: 14
Study 17716544 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato-rich diet (300 g tomatoes daily for 1 month)
Number of subjects: 103
Study 17716544 — intervention group
Group type: COMPARATOR
Intervention: Control diet (usual diet with tomatoes prohibited for 1 month)
Number of subjects: 103
Study 15049460 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation
Number of subjects: 406
Study 15049460 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimicronutrient supplementation
Number of subjects: 406
Study 15049460 — intervention group
Group type: COMPARATOR
Intervention: Control (non-supplementation)
Number of subjects: 406
Study 15049460 — intervention group
Group type: EXPERIMENTAL
Intervention: Geophageous children
Number of subjects: 406
Study 15049460 — intervention group
Group type: EXPERIMENTAL
Intervention: Geophageous children with Hb < 130 g/l
Number of subjects: 406
Study 11682413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (scalp block with 20 mL of ropivacaine 0.75%)
Number of subjects: 30
Study 11682413 — intervention group
Group type: COMPARATOR
Intervention: Saline (scalp block with 20 mL of saline 0.9%)
Number of subjects: 30
Study 11682413 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Number of subjects: 30
Study 11682413 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 9490235 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of C-reactive protein (CRP)
Number of subjects: 144
Study 9490235 — intervention group
Group type: EXPERIMENTAL
Intervention: Quartiles of baseline CRP concentration
Number of subjects: 144
Study 9490235 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CRP levels in case patients requiring revascularization
Number of subjects: 144
Study 8313128 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication
Number of subjects: 61
Study 8313128 — intervention group
Group type: COMPARATOR
Intervention: Angelchik prosthesis
Number of subjects: 61
Study 2901611 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus preparation for 30 days
Number of subjects: 60
Study 2901611 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 60
Study 30968820 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction (CR) for 2 years
Number of subjects: 220
Study 30968820 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum diet (AL)
Number of subjects: 220
Study 31017639 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Prolonged Exposure (I-PE) therapy
Number of subjects: 119
Study 31017639 — intervention group
Group type: COMPARATOR
Intervention: Integrated Coping Skills (I-CS) therapy
Number of subjects: 119
Study 28318759 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma, Sport and Health (ASAH) programme
Number of subjects: 203
Study 28318759 — intervention group
Group type: COMPARATOR
Intervention: Comparison School (CS)
Number of subjects: 203
Study 26236997 — intervention group
Group type: EXPERIMENTAL
Intervention: egg oral immunotherapy (egg‐OIT) for 3 months (maintenance dose one undercooked egg every 48 hours)
Number of subjects: 61
Study 26236997 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) continued egg avoidance diet for 4 months
Number of subjects: 61
Study 23324689 — intervention group
Group type: EXPERIMENTAL
Intervention: ReDO programme (16-week work rehabilitation)
Number of subjects: 42
Study 23324689 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 42
Study 20849371 — intervention group
Group type: EXPERIMENTAL
Intervention: NUTRIOSE®FB10
Number of subjects: 12
Study 20849371 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 12
Study 18074149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftibuten (9 mg/kg once daily for 14 days)
Number of subjects: 365
Study 18074149 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone (50 mg/kg once daily for 3 days) followed by Ceftibuten (for 11 days)
Number of subjects: 365
Study 17044843 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptans (specifically naratriptan, frovatriptan, zolmitriptan)
Number of subjects: 35
Study 17044843 — intervention group
Group type: COMPARATOR
Intervention: Naproxen sodium, magnesium
Number of subjects: 35
Study 12650133 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg thrice weekly
Number of subjects: 0
Study 12650133 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg once daily
Number of subjects: 0
Study 12650133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11557471 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Number of subjects: 58
Study 11557471 — intervention group
Group type: COMPARATOR
Intervention: Gatifloxacin
Number of subjects: 58
Study 9756240 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH (1 U/kg IBW/week in daily subcutaneous injections)
Number of subjects: 20
Study 9756240 — intervention group
Group type: COMPARATOR
Intervention: Placebo (vehicle only)
Number of subjects: 20
Study 8123235 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical salvage following radiotherapy failure
Number of subjects: 88
Study 8123235 — intervention group
Group type: COMPARATOR
Intervention: Primary radiotherapy with surgery reserved for radiotherapy failures
Number of subjects: 88
Study 3051550 — intervention group
Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine and dapsone) administered fortnightly for 2 years
Number of subjects: 48
Study 3051550 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 3051550 — intervention group
Group type: EXPERIMENTAL
Intervention: Maloprim (pyrimethamine and dapsone)
Number of subjects: 48
Study 30612585 — intervention group
Group type: EXPERIMENTAL
Intervention: Burnaid® hydrogel dressing
Number of subjects: 72
Study 30612585 — intervention group
Group type: COMPARATOR
Intervention: Plastic wrap (control)
Number of subjects: 72
Study 29645411 — intervention group
Group type: EXPERIMENTAL
Intervention: Lecture combined with using a smartphone application
Number of subjects: 673
Study 29645411 — intervention group
Group type: COMPARATOR
Intervention: Lecture only
Number of subjects: 673
Study 29645411 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants doing research projects
Number of subjects: 673
Study 25003624 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones 80 mg/day
Number of subjects: 224
Study 25003624 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones 120 mg/day
Number of subjects: 224
Study 25003624 — intervention group
Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 224
Study 23605375 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone treatment
Number of subjects: 17
Study 23605375 — intervention group
Group type: COMPARATOR
Intervention: Control (non-treatment)
Number of subjects: 17
Study 22097197 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower Injection (20 mL in 250 mL 5% glucose injection, administered intravenously once per day for 1-7 days)
Number of subjects: 60
Study 22097197 — intervention group
Group type: COMPARATOR
Intervention: Dextran-40 (administered intravenously once per day for 1-7 days)
Number of subjects: 60
Study 22097197 — intervention group
Group type: EXPERIMENTAL
Intervention: Safflower Injection
Number of subjects: 60
Study 22097197 — intervention group
Group type: COMPARATOR
Intervention: Dextran-40
Number of subjects: 60
Study 22097197 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 19756528 — intervention group
Group type: EXPERIMENTAL
Intervention: DMAE p-Glu
Number of subjects: 0
Study 19756528 — intervention group
Group type: COMPARATOR
Intervention: Scopolamine
Number of subjects: 0
Study 16838647 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon as maintenance therapy following chemotherapy or autologous stem cell transplantation
Number of subjects: 0
Study 16838647 — intervention group
Group type: COMPARATOR
Intervention: Interferon therapy during induction therapy
Number of subjects: 0
Study 16838647 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon as maintenance therapy for patients responding to first-line therapy
Number of subjects: 0
Study 14738559 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with 6 MU IFN alpha daily for 6 weeks, followed by 6 MU three times a week for 18 weeks and then 3 MU three times a week until week 48, plus ribavirin (10 mg/kg/day) and amantadine (200 mg/day)
Number of subjects: 158
Study 14738559 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with 6 MU IFN alpha three times a week for 24 weeks, followed by 3 MU until week 48, plus ribavirin (10 mg/kg/day) and amantadine (200 mg/day)
Number of subjects: 158
Study 14738559 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction therapy with 6 MU IFN alpha daily
Number of subjects: 158
Study 14738559 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy with 6 MU IFN alpha three times a week
Number of subjects: 158
Study 11530657 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral intervention targeting three diabetes-related behaviors
Number of subjects: 0
Study 9350914 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil (0.5 mg) injected into the infarct-related artery shortly after PTCA, followed by oral administration.
Number of subjects: 40
Study 9350914 — intervention group
Group type: COMPARATOR
Intervention: Control group (PTCA alone)
Number of subjects: 40
Study 7900949 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg/day zidovudine
Number of subjects: 1423
Study 7900949 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg/day zidovudine
Number of subjects: 1423
Study 7900949 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1423
Study 3096626 — intervention group
Group type: EXPERIMENTAL
Intervention: Auranofin
Number of subjects: 40
Study 3096626 — intervention group
Group type: COMPARATOR
Intervention: Aurothioglucose
Number of subjects: 40
Study 30588201 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric Exercise (EE) with Vibration training for 12 weeks
Number of subjects: 61
Study 30588201 — intervention group
Group type: COMPARATOR
Intervention: Eccentric Exercise (EE) with Cryotherapy for 12 weeks
Number of subjects: 61
Study 30588201 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (EE with Vibration and EE with Cryotherapy)
Number of subjects: 61
Study 26714179 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative care with frequent followup by a care navigator
Number of subjects: 308
Study 26714179 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 308
Study 25268567 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose progesterone (PG)
Number of subjects: 360
Study 25268567 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 supplementation
Number of subjects: 360
Study 25268567 — intervention group
Group type: COMPARATOR
Intervention: Low-dose progesterone (PG)
Number of subjects: 360
Study 22612244 — intervention group
Group type: EXPERIMENTAL
Intervention: Open reduction and internal fixation (ORIF)
Number of subjects: 94
Study 22612244 — intervention group
Group type: COMPARATOR
Intervention: Minimally invasive percutaneous plate osteosynthesis (MIPPO)
Number of subjects: 94
Study 20485337 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 mg D,L‐sotalol
Number of subjects: 83
Study 20485337 — intervention group
Group type: EXPERIMENTAL
Intervention: 320 mg D,L‐sotalol
Number of subjects: 83
Study 20485337 — intervention group
Group type: COMPARATOR
Intervention: moxifloxacin
Number of subjects: 83
Study 20485337 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 83
Study 18584369 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin (2.5, 5, 7.5, or 10 g) administered intravenously over 7.5 to 30 minutes
Number of subjects: 41
Study 16221780 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body cooling to an esophageal temperature of 33.5 degrees C for 72 hours
Number of subjects: 239
Study 16221780 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 239
Study 11840792 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracameral anesthesia with 0.15 ml lidocaine 1%
Number of subjects: 40
Study 11840792 — intervention group
Group type: COMPARATOR
Intervention: Sponge anesthesia without lidocaine
Number of subjects: 40
Study 10512276 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg/kg phenytoin
Number of subjects: 20
Study 10512276 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 7736649 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure FSH (Metrodin)
Number of subjects: 30
Study 7736649 — intervention group
Group type: COMPARATOR
Intervention: Conventional gonadotropin (Pergonal)
Number of subjects: 30
Study 1999714 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCP/VBAP
Number of subjects: 304
Study 1999714 — intervention group
Group type: COMPARATOR
Intervention: MP
Number of subjects: 304
Study 1999714 — intervention group
Group type: EXPERIMENTAL
Intervention: LI >= 2%
Number of subjects: 304
Study 1999714 — intervention group
Group type: EXPERIMENTAL
Intervention: beta 2-m >= 6 mg/L
Number of subjects: 304
Study 6825391 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Asproclear
Number of subjects: 6
Study 6825391 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Bufferin
Number of subjects: 6
Study 6825391 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg Bi-prin
Number of subjects: 6
Study 6825391 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg compressed ASA
Number of subjects: 6
Study 6825391 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg Ecotrin
Number of subjects: 6
Study 6825391 — intervention group
Group type: EXPERIMENTAL
Intervention: 650 mg S.R.A.
Number of subjects: 6
Study 31476451 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (2.5 g/day)
Number of subjects: 65
Study 31476451 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 28634644 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic medication
Number of subjects: 267
Study 27076592 — intervention group
Group type: EXPERIMENTAL
Intervention: Total and exclusive breastfeeding
Number of subjects: 620
Study 24994919 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxygen administered via nasal cannula
Number of subjects: 0
Study 24994919 — intervention group
Group type: COMPARATOR
Intervention: Room air administered via nasal cannula
Number of subjects: 0
Study 22822043 — intervention group
Group type: EXPERIMENTAL
Intervention: Colloid solution (15 ml kg(‐1) over 30 min)
Number of subjects: 30
Study 22822043 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid solution (15 ml kg(‐1) over 30 min)
Number of subjects: 30
Study 22822043 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (steady-state and dynamic phases)
Number of subjects: 30
Study 20354559 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple-micronutrient supplementation (micronutrient powder, syrup, and milk-based fortified-food supplement)
Number of subjects: 187
Study 20354559 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient-only group (MM)
Number of subjects: 187
Study 20354559 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified-food supplement (FFS)
Number of subjects: 187
Study 20354559 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no supplementation)
Number of subjects: 187
Study 19012672 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise (10 weeks, 3 days a week)
Number of subjects: 30
Study 19012672 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 30
Study 15963096 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (200 mg once daily for 4 days)
Number of subjects: 11
Study 15963096 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (200 mg once daily for 4 days)
Number of subjects: 11
Study 15963096 — intervention group
Group type: COMPARATOR
Intervention: Control (150 microg oral dose of desogestrel alone)
Number of subjects: 11
Study 12796572 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for neonates with meconium aspiration syndrome
Number of subjects: 216
Study 12796572 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO after heart, lung, heart-lung, and liver transplant
Number of subjects: 216
Study 12796572 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for severe asthma
Number of subjects: 216
Study 12796572 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for hydrocarbon aspiration
Number of subjects: 216
Study 12796572 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for congestive heart failure due to cerebral arteriovenous malformation
Number of subjects: 216
Study 12796572 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for tracheal occlusion during endoscopic stent manipulation
Number of subjects: 216
Study 12796572 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for meningitis
Number of subjects: 216
Study 12796572 — intervention group
Group type: EXPERIMENTAL
Intervention: ECMO for viral pneumonia
Number of subjects: 216
Study 12796572 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall ECMO program
Number of subjects: 216